Reaction
Gastrointestinal Stromal Tumour reporting signals
As of the last recalculation, Gastrointestinal Stromal Tumour appears in 2,644 FAERS reports alongside 30 co-occurring drug terms. The strongest observed disproportionality signal is IMATINIB (PRR 174.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Imatinib | 341 | 174.6 | 178.0 |
| Imatinib Mesylate | 476 | 163.6 | 166.5 |
| Sunitinib Malate | 436 | 104.3 | 105.5 |
| Regorafenib | 142 | 101.7 | 102.9 |
| Nilotinib | 66 | 18.0 | 18.1 |
| Basiliximab | 20 | 13.5 | 13.5 |
| Ganciclovir | 16 | 12.4 | 12.4 |
| Ganciclovir Sodium | 16 | 12.0 | 12.0 |
| Valganciclovir Hydrochloride Powder, | 16 | 10.4 | 10.4 |
| Sirolimus | 15 | 8.8 | 8.8 |
| Pazopanib Hydrochloride | 27 | 7.9 | 7.9 |
| Sorafenib | 19 | 7.2 | 7.3 |
| Acalabrutinib | 11 | 7.2 | 7.2 |
| Valganciclovir | 17 | 7.1 | 7.1 |
| Valganciclovir Hydrochloride | 17 | 7.1 | 7.1 |
| Indapamide | 16 | 7.1 | 7.1 |
| Valsartan Oral | 41 | 6.0 | 6.0 |
| Ranitidine Hydrochloride | 37 | 5.4 | 5.4 |
| Everolimus Tablets | 11 | 5.2 | 5.2 |
| Bendamustine Hcl | 10 | 5.1 | 5.1 |
| Atovaquone | 5 | 4.9 | 4.9 |
| Obinutuzumab | 10 | 4.8 | 4.8 |
| Prochlorperazine Maleate | 5 | 4.3 | 4.3 |
| Avapritinib | 5 | 3.3 | 3.3 |
| Crizotinib | 5 | 3.1 | 3.1 |
| Daratumumab | 13 | 2.6 | 2.6 |
| Ranitidine | 59 | 2.4 | 2.4 |
| Dasatinib | 11 | 2.3 | 2.3 |
| Osimertinib | 9 | 2.2 | 2.2 |
| Cabozantinib | 12 | 2.0 | 2.0 |